NVO Novo Nordisk

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Company profile

Lars Fruergaard Joergensen
Fiscal year end

NVO stock data



3 Feb 21
18 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

7.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 686 646 +6.2%
Opened positions 94 55 +70.9%
Closed positions 54 56 -3.6%
Increased positions 225 193 +16.6%
Reduced positions 217 233 -6.9%
13F shares
Current Prev Q Change
Total value 9.52B 10.04B -5.2%
Total shares 136.33M 139.26M -2.1%
Total puts 750K 341.4K +119.7%
Total calls 890.1K 781.7K +13.9%
Total put/call ratio 0.8 0.4 +92.9%
Largest owners
Shares Value Change
Renaissance Technologies 26.84M $1.87B -4.6%
Fisher Asset Management 15.83M $1.11B +0.8%
BAC Bank Of America 7.56M $528.05M -4.7%
Loomis Sayles & Co L P 6.82M $476.7M -6.2%
Folketrygdfondet 5.66M $395.65M +2.5%
Fayez Sarofim & Co 4.98M $348.1M -0.3%
Capital International Investors 4.72M $330.47M +3.0%
STT State Street 4.17M $291.08M -0.2%
State Farm Mutual Automobile Insurance 3.48M $243.01M 0.0%
Everett Harris & Co 3.22M $225.07M +0.6%
Largest transactions
Shares Bought/sold Change
Renaissance Technologies 26.84M -1.28M -4.6%
Eaton Vance Management 463.99K -702.33K -60.2%
Arrowstreet Capital, Limited Partnership 666.34K -579.69K -46.5%
Loomis Sayles & Co L P 6.82M -454.92K -6.2%
BAC Bank Of America 7.56M -370.25K -4.7%
Jennison Associates 667.77K -340.6K -33.8%
Orbimed Advisors 0 -330K EXIT
CS Credit Suisse 104.98K -321.36K -75.4%
Two Sigma Advisers 30.7K -288K -90.4%
Old Mission Capital 264.89K +264.89K NEW
Content analysis
8th grade Avg
New words: adjunct, Adult, airfreight, analogue, border, broad, confidence, dealt, declared, diet, distancing, Dr, Durable, EMEA, encompassed, force, FTA, glance, Glucagen, glycemic, hemophilia, hereof, highly, icodec, inflationary, interchangeability, inventory, job, judgment, kidney, lifted, lost, magnitude, Mainland, mg, MRA, Mutual, NI, Northern, NovoThirteen, paediatric, pandemic, Pfizer, pose, predicted, Protocol, rebuilding, Rest, retesting, Sandoz, seek, slightly, Sogroya, Sonion, transportation, Tretten, unemployment, unvested, withdrew
Removed: AAMEO, activity, adjusted, adjusting, advanced, aim, allocation, anticipated, Article, Azerbaijan, base, bearing, biotechnological, Brandgaard, broader, build, capture, capturing, chemistry, close, clotting, coagulation, committed, conform, congenital, counterparty, deferred, deficiency, develop, differentiated, digit, dual, ease, efficiency, employment, equivalent, evidenced, exerting, extraordinary, factor, filling, financing, FlexPro, formally, fulfilled, fulfilling, FVII, generate, generated, genetic, high, humanitarian, Iceland, inapplicable, inject, insignificant, Instance, intangible, investing, Jesper, Kazakhstan, Korea, large, largely, liable, manufacturer, marketable, meaningful, measure, metric, milestone, Norway, numerator, original, payout, peer, pen, perspective, played, predefined, presence, producing, prospective, protein, readily, recombinant, reconciliation, recruiting, reducing, regularly, relate, released, rendering, replacement, request, rFVIIa, Russia, secure, sourcing, stability, stable, strength, sum, supplied, Sylvie, tel, temperature, tender, turnover, understand, undrawn, unforeseen, upfront, USA, utilize, Uzbekistan, VIIa, volatility, widely


No filings


Drug delivery device with information capture
30 Nov 20
A drug delivery device is provided comprising or adapted to receive a cartridge with an axially displaceable piston.
Power Unit for Drug Delivery Device
25 Nov 20
The present invention provides a power unit (1) for a drug delivery device as well as methods for providing and mounting the power unit (1) in the drug delivery device.
An Injection Device With Needle Cleaning
18 Nov 20
The invention relates to a medical injection device having a needle cannula for multiple use and which needle cannula is cleaned between subsequent injections.
Drug Injection Device with Deflectable Transducer
18 Nov 20
The present invention provides a drug injection device (100, 100′, 100″) comprising a first element (130) and a second element (102, 102′, 102″) configured to undergo movement relative to each other corresponding to an action performed on or by the drug injection device (100, 100′, 100″), wherein the first element (130) comprises serially disposed protrusions (133), and wherein the second element (102, 102′, 102″) comprises a second element base and a deflectable transducer (170, 170′, 170″).
Stable multi-dose compositions comprising an antibody and a preservative
16 Nov 20
The invention relates to stable, multi-dose liquid compositions containing proteins, in particular, but not exclusively stable antibodies, and to the use of said compositions in therapy, in particular for the subcutaneous delivery of said stable protein.